Abdominal Pain
Conditions
Brief summary
In children 7-12 years of age with functional abdominal pain (n=42) determine: Aim 1 - To examine and characterize the threshold of the exposure (PK) vs. response (PD) relationship of PMO (menthol) Aim 2 - PD of PMO as assessed by: 1. Microbiome composition (16S RNA sequencing) 2. Transit rate/contractile activity (using the SmartPill®) Aim 3 - Evaluate the potential association between PD response and clinical symptoms (abdominal pain and stooling pattern via validated diary), psychosocial distress (anxiety, depression, somatization), and characterize potential side effects (questionnaire)
Detailed description
An initial single-dose PK study will be carried out. Forty-two children (n=21 per dose) will be randomized to receive approximately 10.9 mg·kg-1·d-1 of PMO or to receive approximately 18.2 mg·kg-1·d-1 (1.67-fold the median dose). Following the single-dose PK study, a PD study will be carried out wherein the subjects will receive their assigned dose of PMO for 7 days. At baseline (before the PK study) and after the PK study (i.e., during the PD study), subjects will keep a pain and stooling diary, collect stool for microbiome analysis, and swallow a SmartPill to measure gut motility and transit time. At baseline only, anxiety, depression, somatization will be measured. During the PD study, any side effects will be recorded.
Interventions
DRUGPeppermint oil
Administration of peppermint oil at one of two daily doses.
Sponsors
Baylor College of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Children ages 7-12 years who are able to assent to the procedures * Able to complete the diaries which have been validated for use in this age range * The history and medical evaluation reveal no organic reason for the abdominal pain * The child has abdominal pain that meets the definition of FAP according to pediatric Rome IV * Ability to understand study procedures and to comply with them for the entire length of the study * Childrens' body weights will not vary by more than 10-15 kg (so that dose per kg is comparable within the two dosing groups)
Exclusion criteria
* Past bowel surgery * Documented GI disorders (e.g., Crohn's disease) * A serious chronic medical condition (e.g., diabetes) * A weight and/or height \< 2 SD for age * Chronic conditions with GI symptoms (e.g., cystic fibrosis) * Autism spectrum disorder, significant developmental delay, psychosis, depression, or a history of bipolar disorder * Antibiotic/probiotic treatment within 2 mo. * Allergy/sensitivity to PMO or its ingredients * Inability to swallow the PMO capsule or the SmartPill® * Inability to speak English - testing materials are available only in this language * Unable to discontinue laxative, prokinetic, or neuromodulator from 3 wk prior to Visit 1 through the end of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of peppermint oil | 2 weeks | Area under the curve |
| Gut Microbiome composition | 2 weeks | Gut microbiome composition as determined by 16S sequencing as a consequence of the administration of peppermint oil at the two doses given. |
| Gut transit time | 2 weeks | Gut transit time as a consequence of the administration of peppermint oil at the two doses given. |
| Gut contractility | 2 weeks | Gut contractility as a consequence of the administration of peppermint oil at the two doses given. |
Countries
United States
Outcome results
None listed